Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

Mary M. Taj; Nedim Hadzic; Sue Height; Andrew Wotherspoon; Margaret Burke; Rachel Hobson; Maria Viskaduraki; C. Ross Pinkerton

doi:10.3109/10428194.2011.634045

Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

Mary M. Taj^*, Nedim Hadzic, Sue Height, Andrew Wotherspoon, Margaret Burke, Rachel Hobson, Maria Viskaduraki, C. Ross Pinkerton

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Prospective national registry data on 98 patients were studied to determine the long-term outcome of immune related lymphoproliferative disease (LPD) and define prognostic factors. Seventy-three developed LPD following organ transplant (26 liver, 21 heart, 15 kidney, nine bone marrow [BM], two bowel). Twenty-five had non-transplant related immunosuppression. Age was 1.1-17 years (median 8.6). Fifty-eight patients had lymphomatous, 21 systemic and 17 lymphadenopathic disease. Sixty (73%) were disseminated and 22 (27%) localized. Thirty-three (54%) were monoclonal. Seventy-three (83%) were Epstein-Barr virus (EBV) positive. Median follow-up was 7.6 years. LPD developed earlier after liver and BM as compared to heart or kidney transplant. Five-year overall survival (OS) was 58%. Prognosis was best after liver and kidney transplant (OS >77%). Mortality was higher following heart (2.5 times) and BM transplant (5 times). Adverse prognostic factors were disseminated or lymphomatous disease and lack of reduction of immunosuppression. With appropriate reduction of immunosuppression, rituximab and low-dose chemotherapy, long-term survival is high.

Original language	English
Pages (from-to)	842-848
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	53
Issue number	5
DOIs	https://doi.org/10.3109/10428194.2011.634045
Publication status	Published - May 2012

Keywords

Lymphoma and Hodgkin disease
chemotherapeutic approaches
prognostication
EPSTEIN-BARR-VIRUS
STEM-CELL TRANSPLANTATION
SOLID-ORGAN TRANSPLANTATION
EBV REACTIVATION
LIVER-TRANSPLANTATION
RISK-FACTORS
VIRAL-LOAD
RITUXIMAB
DISEASE
CHEMOTHERAPY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2011.634045

Cite this

Taj, M. M., Hadzic, N., Height, S., Wotherspoon, A., Burke, M., Hobson, R., Viskaduraki, M., & Pinkerton, C. R. (2012). Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. Leukemia and Lymphoma, 53(5), 842-848. https://doi.org/10.3109/10428194.2011.634045

@article{57846e63287e46f3aaa003084d1d9052,

title = "Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004",

abstract = "Prospective national registry data on 98 patients were studied to determine the long-term outcome of immune related lymphoproliferative disease (LPD) and define prognostic factors. Seventy-three developed LPD following organ transplant (26 liver, 21 heart, 15 kidney, nine bone marrow [BM], two bowel). Twenty-five had non-transplant related immunosuppression. Age was 1.1-17 years (median 8.6). Fifty-eight patients had lymphomatous, 21 systemic and 17 lymphadenopathic disease. Sixty (73%) were disseminated and 22 (27%) localized. Thirty-three (54%) were monoclonal. Seventy-three (83%) were Epstein-Barr virus (EBV) positive. Median follow-up was 7.6 years. LPD developed earlier after liver and BM as compared to heart or kidney transplant. Five-year overall survival (OS) was 58%. Prognosis was best after liver and kidney transplant (OS >77%). Mortality was higher following heart (2.5 times) and BM transplant (5 times). Adverse prognostic factors were disseminated or lymphomatous disease and lack of reduction of immunosuppression. With appropriate reduction of immunosuppression, rituximab and low-dose chemotherapy, long-term survival is high.",

keywords = "Lymphoma and Hodgkin disease, chemotherapeutic approaches, prognostication, EPSTEIN-BARR-VIRUS, STEM-CELL TRANSPLANTATION, SOLID-ORGAN TRANSPLANTATION, EBV REACTIVATION, LIVER-TRANSPLANTATION, RISK-FACTORS, VIRAL-LOAD, RITUXIMAB, DISEASE, CHEMOTHERAPY",

author = "Taj, {Mary M.} and Nedim Hadzic and Sue Height and Andrew Wotherspoon and Margaret Burke and Rachel Hobson and Maria Viskaduraki and Pinkerton, {C. Ross}",

year = "2012",

month = may,

doi = "10.3109/10428194.2011.634045",

language = "English",

volume = "53",

pages = "842--848",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

Taj, MM, Hadzic, N, Height, S, Wotherspoon, A, Burke, M, Hobson, R, Viskaduraki, M & Pinkerton, CR 2012, 'Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004', Leukemia and Lymphoma, vol. 53, no. 5, pp. 842-848. https://doi.org/10.3109/10428194.2011.634045

Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004. / Taj, Mary M.; Hadzic, Nedim; Height, Sue et al.
In: Leukemia and Lymphoma, Vol. 53, No. 5, 05.2012, p. 842-848.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term outcome for immune suppression and immune related lymphoproliferative disorder

T2 - prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

AU - Taj, Mary M.

AU - Hadzic, Nedim

AU - Height, Sue

AU - Wotherspoon, Andrew

AU - Burke, Margaret

AU - Hobson, Rachel

AU - Viskaduraki, Maria

AU - Pinkerton, C. Ross

PY - 2012/5

Y1 - 2012/5

N2 - Prospective national registry data on 98 patients were studied to determine the long-term outcome of immune related lymphoproliferative disease (LPD) and define prognostic factors. Seventy-three developed LPD following organ transplant (26 liver, 21 heart, 15 kidney, nine bone marrow [BM], two bowel). Twenty-five had non-transplant related immunosuppression. Age was 1.1-17 years (median 8.6). Fifty-eight patients had lymphomatous, 21 systemic and 17 lymphadenopathic disease. Sixty (73%) were disseminated and 22 (27%) localized. Thirty-three (54%) were monoclonal. Seventy-three (83%) were Epstein-Barr virus (EBV) positive. Median follow-up was 7.6 years. LPD developed earlier after liver and BM as compared to heart or kidney transplant. Five-year overall survival (OS) was 58%. Prognosis was best after liver and kidney transplant (OS >77%). Mortality was higher following heart (2.5 times) and BM transplant (5 times). Adverse prognostic factors were disseminated or lymphomatous disease and lack of reduction of immunosuppression. With appropriate reduction of immunosuppression, rituximab and low-dose chemotherapy, long-term survival is high.

AB - Prospective national registry data on 98 patients were studied to determine the long-term outcome of immune related lymphoproliferative disease (LPD) and define prognostic factors. Seventy-three developed LPD following organ transplant (26 liver, 21 heart, 15 kidney, nine bone marrow [BM], two bowel). Twenty-five had non-transplant related immunosuppression. Age was 1.1-17 years (median 8.6). Fifty-eight patients had lymphomatous, 21 systemic and 17 lymphadenopathic disease. Sixty (73%) were disseminated and 22 (27%) localized. Thirty-three (54%) were monoclonal. Seventy-three (83%) were Epstein-Barr virus (EBV) positive. Median follow-up was 7.6 years. LPD developed earlier after liver and BM as compared to heart or kidney transplant. Five-year overall survival (OS) was 58%. Prognosis was best after liver and kidney transplant (OS >77%). Mortality was higher following heart (2.5 times) and BM transplant (5 times). Adverse prognostic factors were disseminated or lymphomatous disease and lack of reduction of immunosuppression. With appropriate reduction of immunosuppression, rituximab and low-dose chemotherapy, long-term survival is high.

KW - Lymphoma and Hodgkin disease

KW - chemotherapeutic approaches

KW - prognostication

KW - EPSTEIN-BARR-VIRUS

KW - STEM-CELL TRANSPLANTATION

KW - SOLID-ORGAN TRANSPLANTATION

KW - EBV REACTIVATION

KW - LIVER-TRANSPLANTATION

KW - RISK-FACTORS

KW - VIRAL-LOAD

KW - RITUXIMAB

KW - DISEASE

KW - CHEMOTHERAPY

U2 - 10.3109/10428194.2011.634045

DO - 10.3109/10428194.2011.634045

M3 - Article

SN - 1042-8194

VL - 53

SP - 842

EP - 848

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -

Long-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this